AstraZeneca (LON:AZN) Price Target Raised to £120

AstraZeneca (LON:AZN) had its price target raised by Deutsche Bank Aktiengesellschaft from £117 to £120 in a report published on Friday,Digital Look reports. Deutsche Bank Aktiengesellschaft currently has a hold rating on the biopharmaceutical company’s stock.

Other research analysts have also recently issued research reports about the company. Citigroup lifted their target price on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Jefferies Financial Group restated a “buy” rating and set a £175 price target on shares of AstraZeneca in a research note on Friday, October 30th. Royal Bank Of Canada began coverage on AstraZeneca in a report on Tuesday, September 8th. They issued an “outperform” rating and a £145 price objective on the stock. Finally, Berenberg Bank restated a “buy” rating and issued a £175 price objective on shares of AstraZeneca in a report on Wednesday, October 7th. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and an average target price of £155.50.

AstraZeneca Trading Up 1.3%

Shares of AZN stock traded up GBX 185.09 on Friday, reaching £141.15. 19,870,375 shares of the stock were exchanged, compared to its average volume of 30,170,758. The stock has a market cap of £218.91 billion, a P/E ratio of 19.99, a price-to-earnings-growth ratio of 0.86 and a beta of 0.21. The company has a quick ratio of 0.59, a current ratio of 1.01 and a debt-to-equity ratio of 66.10. The firm has a 50 day moving average of £124.76 and a two-hundred day moving average of £134.29. AstraZeneca has a 1-year low of £114.04 and a 1-year high of £157.32.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Michel Demare acquired 2,500 shares of the firm’s stock in a transaction on Monday, September 14th. The stock was bought at an average cost of £121.21 per share, for a total transaction of £303,025. 0.15% of the stock is currently owned by corporate insiders.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.